(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a ...

The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Consumers who take GLP-1 drugs might switch what they eat, but they largely spend the same amount of money on CPG food and ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Gemma left some of her 2.2 million social media followers in awe when she mentioned she had partnered with Yazen, a company ...

A new report from AARP Public Policy Institute found that the top 25 drugs prescribed under Medicare Part D have nearly ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

Gemma said she’d decided to start taking medication - which is listed on Yazen’s website as GLP-1 weight loss injections - ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...